Lyell Immunopharma (LYEL) Free Cash Flow (2020 - 2026)

Lyell Immunopharma has reported Free Cash Flow for 7 years, with the latest figure at -$38.6 million in Q1 2026.

• Quarterly Free Cash Flow rose 29.68% year-over-year to -$38.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$134.5 million (up 23.31% YoY) and the FY2025 annual result came in at -$150.8 million, up 7.22% from the prior year.
• Free Cash Flow declined to -$38.6 million in Q1 2026 per LYEL's latest filing, from -$33.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$21.9 million in Q4 2022 and troughed at -$54.9 million in Q1 2025.
• A 5-year average of -$40.5 million and a median of -$40.1 million in 2023 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 76.53% in 2022, down 118.71% in 2022.
• Over 5 years, Free Cash Flow stood at -$21.9 million in 2022, then sank by 97.82% to -$43.3 million in 2023, then declined by 8.42% to -$47.0 million in 2024, then increased by 29.67% to -$33.0 million in 2025, then fell by 16.86% to -$38.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$38.6 million, -$33.0 million, and -$28.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.